Laekna, Inc. (02105)
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People's Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
